P53 mutations are reported in 11.1% of patients with papillary carcinoma, 14.3% with follicular carcinoma and 63% with anaplastic carcinoma (in some studies mentioned to be between 75 to 83.3%). Here, TP53 is linked to undifferentiated carcinoma.